Sanuwave Health (NASDAQ:SNWV) Posts Earnings Results, Misses Expectations By $0.14 EPS

Sanuwave Health (NASDAQ:SNWV) issued its earnings results on Thursday. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.14), FiscalAI reports. The business had revenue of $13.09 million for the quarter, compared to analyst estimates of $13.23 million.

Sanuwave Health Stock Performance

NASDAQ SNWV traded down $1.08 during trading hours on Thursday, hitting $18.85. The company had a trading volume of 153,654 shares, compared to its average volume of 59,937. The company has a market cap of $161.73 million, a PE ratio of -14.50 and a beta of 1.32. The business has a 50 day moving average of $24.37 and a 200-day moving average of $29.62. Sanuwave Health has a 1-year low of $18.61 and a 1-year high of $46.58.

Institutional Investors Weigh In On Sanuwave Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in shares of Sanuwave Health during the second quarter worth $26,000. BNP Paribas Financial Markets bought a new stake in shares of Sanuwave Health during the 2nd quarter valued at about $46,000. Russell Investments Group Ltd. acquired a new stake in Sanuwave Health during the third quarter worth about $67,000. New York State Common Retirement Fund bought a new position in Sanuwave Health in the second quarter worth about $102,000. Finally, JPMorgan Chase & Co. bought a new position in Sanuwave Health in the second quarter worth about $109,000. Hedge funds and other institutional investors own 42.53% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sanuwave Health in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Sanuwave Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.